Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)
Colorado Prevention Center
Summary
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Description
This is an international, randomized, controlled, open-label, trial of an early, intensive management strategy using the combination of finerenone plus sodium-glucose co-transporter 2 inhibitor (SGLT2i) compared with usual care in patients hospitalized with heart failure (HF).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations * Age ≥18 years or legal age of majority if \>18 years in the participant's country of residence * Current hospitalization or recently discharged with the primary diagnosis of heart failure * Heart failure signs and symptoms at the time of hospital admission * Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg/mL or B-type natriuretic peptide (BNP) ≥125 pg/mL according to the local lab for patients in sinus…
Interventions
- DrugFinerenone
Oral finerenone.
- DrugEmpagliflozin
Oral empagliflozin.
Locations (15)
- CON-10004 Fairhope, AL Investigational SiteFairhope, Alabama
- CON-10075 El Centro, CA Investigational SiteEl Centro, California
- CON-10024 Sacramento, CA Investigational SiteSacramento, California
- CON-10022 Atlanta, GA Investigational SiteAtlanta, Georgia
- CON-10030 Baton Rouge, LA Investigational SiteBaton Rouge, Louisiana
- CON-10002 Kansas City, MO Investigative SiteKansas City, Missouri